New weight-loss drug aims for lasting results in large phase 3 trial

NCT ID NCT07684235

Not yet recruiting Disease control Sponsor: Amgen Source: ClinicalTrials.gov ↗

First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time

Summary

This phase 3 trial tests whether the drug maridebart cafraglutide (MariTide) can help people with obesity or overweight lose weight and keep it off over the long term. Participants who completed an earlier trial will receive either the drug or a placebo. The study measures weight change and monitors for side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: maridebart cafraglutide (MariTide)
What this could lead to: If successful, this could provide a long-term treatment option for significant and sustained weight loss in people with obesity or overweight.
What could go wrong: This is an extension trial, so results depend on earlier findings. Weight loss may vary, and side effects are possible. Long-term safety is still being evaluated.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY OVERWEIGHT

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.